Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for XARELTO, a human drug product, and is publishing this notice as required by law. The determination was made due to a patent extension application submitted to the Director of Patents and Trademarks, Department of Commerce.